NCT00326950View on ClinicalTrials.gov

Phase I Clinical Study of E7389

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

February 29, 2008

Conditions
Cancer
Interventions
DRUG

E7389

E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.

Trial Locations (1)

277-0882

Kashiwa

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT00326950 - Phase I Clinical Study of E7389 | Biotech Hunter | Biotech Hunter